Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease

Shilpa Ramaswamy, Jodi L. McBride, Christopher D. Herzog, Eugene Brandon, Mehdi Gasmi, Raymond T. Bartus, Jeffrey H. Kordower

    Research output: Contribution to journalArticle

    28 Scopus citations

    Abstract

    Huntington's disease (HD) is a devastating neurodegenerative disease characterized by the selective loss of neurons in the striatum and cerebral cortex. This study tested the hypothesis that an adenoassociated viral (AAV2) vector encoding for the trophic factor neurturin (NTN) could provide neuroprotection in the rat 3-nitropropionic acid (3NP) model of HD. Rats received AAV2-NTN (CERE-120), AAV2-eGFP or Vehicle, followed 4 weeks later by the mitochondrial toxin 3NP. 3NP induced motor impairments were observed on the rotarod test, the platform test, and a clinical rating scale in all groups. However, each of these deficits was attenuated by AAV2-NTN (CERE-120). Stereological counts revealed a significant protection of NeuN-ir striatal neurons from 3NP toxicity by AAV2-NTN. These data support the concept that AAV2-NTN might be a valuable treatment for patients with Huntington's disease.

    Original languageEnglish (US)
    Pages (from-to)375-384
    Number of pages10
    JournalNeurobiology of Disease
    Volume26
    Issue number2
    DOIs
    StatePublished - May 1 2007

    Keywords

    • 3-Nitropropionic acid
    • Adenoassociated viral vector
    • Gene therapy
    • Huntington's disease
    • Neurturin

    ASJC Scopus subject areas

    • Neurology

    Fingerprint Dive into the research topics of 'Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease'. Together they form a unique fingerprint.

  • Cite this